Today's News |
Richmond-based Biolytical Laboratories Develops 60-Second Ebola Testing Kit
Thursday, October 30, 2014
Vancouver, BC, October 30, 2014--(T-Net)--bioLytical Laboratories, a leader in rapid infectious disease diagnostic tests, announced today that it has successfully developed a pre-clinical prototype diagnostic test for the rapid detection of antibodies to the Ebola Zaire strain responsible for the current outbreak in West Africa.
The prototype is based upon the Company's proven, accurate, and highly accepted INSTI rapid test platform, which is capable of providing results in as little as 60 seconds, according to the company.
"We are very excited about what our research and development team has been able to accomplish in such a short period of time," says bioLytical's Chief Executive Officer Dr. Christopher Shackleton.
"There is clearly a pressing need for a diagnostic test that can rapidly and accurately detect the presence of this potentially deadly infection as early as possible and in diverse testing environments. We also believe that the speed of our INSTI platform will offer considerable advantages as compared to slower point-of-care assays when it comes to the screening of large numbers of subjects in the field as well as in those settings where time is a significant constraint such as travel points of entry."
bioLytical Chairman Robert Mackie adds, "This test is a significant step forward in the battle to contain the current Ebola epidemic, and bioLytical is continuing to work with international authorities to ensure that we're contributing to the containment efforts."
bioLytical Laboratories is a privately owned Canadian biotechnology company engaged in the development and manufacture point-of-care rapid diagnostic tests. Its flagship product is the 60-second INSTI HIV1/HIV2 antibody test - the world's fastest.
For more information visit www.bioLytical.com.
ABOUT BIOLYTICAL LABORATORIES
Biolytical Laboratories Inc. based in Richmond, BC, Canada is a privately-owned Canadian Company federally incorporated in 2002. Our mission is to improve the quality of people's lives by providing innovative solutions for infectious disease diagnosis, the first step in the linkage of patients to appropriate care and treatment. Today, the company sells and markets its INSTI™ HIV test supported by worldwide regulatory approvals including US FDA approval, Health Canada approval and CE mark in Europe.
Our product provides a highly accurate HIV test result in as little as 60 seconds which translates into a compelling value proposition for patients, healthcare professionals, payers and public health organizations. We have an active R&D program and our pipeline includes INSTI™ tests for diseases such as Hepatitis C and Syphilis. The company also provides contract services to adapt the INSTI™ platform to meet custom functional and technical diagnostic testing requirements.
Our vision is to be a global leader in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostic devices.